AI주식인사이트AI Stock Insight
C

코오롱티슈진

950160KOSDAQ

45.0 / 100

Reference Date: 2026-10-23

Financial Score18.5 / 40
News Sentiment12.5 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly down 2.4% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Koongtishujin is a biotech company developing cell gene therapy drugs using its TG-C platform, currently conducting Phase III clinical trials for knee osteoarthritis and Phase II trials for hip osteoarthritis. As of July 2024, the Phase III trial for knee osteoarthritis has enrolled 1,066 patients. The company also operates a complex distribution business, selling health supplements, cosmetics, and wines through its W-store and L&B segments.

Number of Employees

58people

Average Salary

163.1M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
—Industry Average 1.203.5Point
ROE
-188.19Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
6.60Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲14.3% (2-year basis)

Operating Profit Growth Rate
0.5 / 3

Avg ▼0.0% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -77.0% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 15,450Won52-week high 138,80052-week low 11,670
1-month return2.0Point

1m -2.40% (slight drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0